OTTAWA, Ontario, Nov. 04, 2025 (GLOBE NEWSWIRE) — Habitat for Humanity Canada welcomes the federal government's continued investments in housing in Budget 2025, but urges Ottawa to quickly share how these measures will meet Canadians' aspirations to own a home. The organization looks forward to seeing a Build Canada Homes investment strategy and stresses the […]
Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for
Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for
Habitat for Humanity Canada Responds to Federal Budget 2025 with Calls for Clear Commitment to Affordable Homeownership GlobeNewswire November 05, 2025 OTTAWA, Ontario, Nov. 04, 2025 (GLOBE NEWSWIRE) — Habitat for Humanity Canada welcomes the federal government's continued investments in housing in Budget 2025, but urges Ottawa to quickly share how these measures will meet
NEW YORK, NY / ACCESS Newswire / November 4, 2025 / If you suffered a loss on your KBR, Inc. (NYSE:KBR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kbr-inc-lawsuit-submission-form?prid=175539&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NAPERVILLE, IL / ACCESS Newswire / November 4, 2025 / Final Moment, a technology company focused on transforming how people preserve memories and communicate beyond life, has officially announced the launch of its innovative online memorial platform. Designed for individuals and families seeking a modern approach to legacy creation, the platform empowers users to record,
(NASDAQ:HCM),(LSE – AIM:HCM),(HKSE:0013), HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS(R) (savolitinib) and TAGRISSO(R) (osimertinib) for the treatment of patients with epidermal growth factor receptor (“EGFR”)-mutated, MET-overexpressed
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric fusion protein) were showcased at American College of Rheumatology
NEW YORK CITY, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and certain officers.�� The class action, filed in the United States District Court for the Southern District of New York, and docketed under 25-cv-08912,
NEW YORK, NY / ACCESS Newswire / November 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Varonis Systems, Inc. ("Varonis" or the "Company") (NASDAQ:VRNS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Varonis and certain of its officers and/or directors